Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

New exchange: Nasdaq First North

FluoGuide A/S – Flagging message

Okategoriserade


June 1, 2021

Copenhagen, Denmark, 1 June 2021, FluoGuide A/S (“FluoGuide” or “the Company”) hereby announce that Arbejdernes Landsbank has informed the Company that they have 581.604 shares which corresponds to 5,14 percent of all shares in the Company.

 

For further information, please contact:
Henrik Moltke
FluoGuide A/S
Phone: +45 22 44 54 04
E-mail: hm@fluoguide.com

Certified Adviser:

Svensk Kapitalmarknadsgransking AB

Phone: +46 70 755 95 51

E-mail: ca@skmg.se

About FluoGuide
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is conducting a proof-of-concept clinical study (phase I/II) to demonstrate the effect of FG001 in patients with high grade glioma. FluoGuide is listed on Nasdaq First North Sweden under the ticker “FLUO”.